REC-163964 is under clinical development by Recursion Pharmaceuticals and currently in Phase II for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase II drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how REC-163964’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
REC-163964 overview
REC-163964 is under development for the treatment of clostridium difficile colitis. It is a repurposed drug that is developed based on combination of artificial intelligence, automation and experimental biology. It is administered through oral route. It acts as selectively inhibitor of clostridium difficile toxins.
Recursion Pharmaceuticals overview
Recursion Pharmaceuticals (Recursion) is a clinical-stage biotech company. It harnesses the Recursion Operating System (OS) technology platform to develop drugs. The company has a pipeline of internally developed clinical and preclinical programs for precision oncology and genetically induced rare diseases with unmet medical need. The company’s pipeline includes REC-994, an orally bioavailable small molecule superoxide scavenger that treats cerebral cavernous malformation (CCM); REC-2282, a central nervous system (CNS)-penetrant, orally bioavailable, small molecule pan-HDAC inhibitor that targets neurofibromatosis type 2; REC-4881 that treats familial adenomatous polyposis (FAP); REC-3964 for clostridioides difficile infection; and RBM39 for advanced HR-proficient ovarian cancers. It operates through subsidiaries in Canada, the US and the UK. Recursion is headquartered in Salt Lake City, Utah, the US.
For a complete picture of REC-163964’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
